Home / Investors / Overview

Company Information

CymaBay Therapeutics (NASDAQ: CBAY)

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting


CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis


CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Q2 2016 Quarterly Results